Phase 4 N=23 A Pharmacokinetic Study of CellCept (Mycophenolate Mofetil) Versus Mycophenolate Sodium in Kidney Transplant Patients
Kidney Transplantation
Primary: Pre-dose Trough Concentration (C0) — 2.387; 2.944 mg/L — p=0.8055
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Combined Electroencephalogram, Magnetic Resonance Imaging-Positron Emission Tomography of Dexmedetomidine Induced Sleep
Dexmedetomidine Induced Sedation
Primary: Number of Participants With Changes in the Brains Default Mode Network. — 16 participants
Phase 3 N=57 Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder
Non-24-Hour Sleep-Wake Disorder
Primary: Maintenance of Entrainment (aMT6s) in Subjects With N24HSWD. — 9; 2 participants
Phase 3 N=324 Efficacy and Safety Study of Shenwu Capsule
Mild Cognitive Impairment
Primary: Change in Cognitive Scores: Alzheimer Disease Assessment Scale-cognitive. Subscale (ADAS-cog) — -4.23; -4.31 units on a scale
Phase 3 N=20 Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
HIV · Hyperlipidemia · Hypertriglyceridemia
Primary: Change From Baseline Triglycerides — 125 units on a scale
Phase 4 N=127 Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy.
Myofascial Pain Syndrome · Pain · Myofascial Trigger Point Pain
Primary: Visual Analogue Scale — 40.8; 44.2; 37.8 units on a scale
Phase 3 N=663 CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)
Lymphocytic Leukemia, Chronic
Primary: Progression-free Survival (PFS) — 15.7; 28.9 months — p=<0.0001
N/A N=53 Multifactorial Approach to Emergent Cerclage
Cervical Insufficiency
Primary: Gestational Latency Achieved Between Cerclage Placement and Time of Delivery — 80; 97 days — p=0.018
N/A N=118 Illness Management and Recovery for Veterans With Severe Mental Illness
Schizophrenia · Schizo-affective Disorder
Primary: Illness Management Ratings — 3.5; 3.3; 3.5; 3.6 units on a scale — p=.8868
Phase 3 N=759 A Study in Adults With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c) — -1.286; -1.338 percentage of glycosylated hemoglobin — p=0.403
N/A N=109 Using MOVE! With Seriously Mentally Ill Veterans
Mental Illness · Obesity
Primary: Weight Measurement — 237.2; 230.2; 240.8; 228.1 pounds — p=.720
Phase 2 N=137 Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
Lupus Nephritis · Lupus Erythematosus, Systemic
Primary: Number of Participants With Complete Response — 22; 21 participants — p=0.85
Phase 2 N=55 A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
Hyperphosphatemia · End-stage Renal Disease
Primary: The Difference in Serum Phosphorus Between Baseline (Day 0) and End of Treatment (Day 28) — 5.9; 5.4 mg/dL
Phase 4 N=35 Vitamin D Plus Fluticasone Propionate
Seasonal Allergic Rhinitis
Primary: Change From Baseline in Total Nasal Symptom Score (TNSS) Over 2 Week Randomized Treatment Period — -11.3; -7.6 units on a scale — p=0.09
Phase 3 N=447 Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
Treatment Outcome
Primary: Change From Baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 8 — 8.8; 6.6 scores on a scale — p=0.013